All articles by Urtė Fultinavičiūtė
Urtė Fultinavičiūtė
@ufulti
Urtė Fultinavičiūtė is a healthcare reporter for Clinical Trials Arena. Urtė's coverage focuses on clinical data management and clinical strategy. Urtė holds an MA in International Journalism from City, University of London.
FT Summit: AI and regulatory changes at the forefront of industry’s mind
At the FT Global Pharma and Biotech Summit in London, various industry players shared their thoughts on technological and regulatory advancements.
GSK’s RSV vaccine Arexvy effective in adults aged 50-59 years
GSK plans to submit the data to regulatory agencies to support label expansion for Arexvy in the younger adult patient population in 2024.
Can a nasal spray tackle agitation in autism?
Despite the need, children with autism spectrum disorder are left with few difficult-to-administer off-label medications to treat agitation.
California’s low-cost insulin plans receive $100m manufacturing boost
Governor Newsom unveils plans to work with a CMO to produce low-cost insulin, even though most insulin is currently produced in-house by big pharma.
Covid-19 vaccines targeting Omicron variants expected to be ready this autumn
Leading mRNA Covid-19 vaccine developers race to get their variant-specific boosters authorized, as newer subvariants start to become dominant.
Lilly eyes weight loss arena for diabetes drug tirzepatide after positive data
The company plans to pursue an expedited approval as an obesity treatment after the recently approved diabetes drug shows weight reduction benefits.
Medication abortion: what to know about its use and access
Prescription drugs used for medical abortion have come under the spotlight with possible restrictions on the horizon in the US.
Cell & gene therapy society establishes working group to tackle Expanded Access misuse
The ISCT Expanded Access Working Group will focus on identifying regulatory and ethical issues within the unapproved CGT sector.